JO3592B1 - شكل بلوري جديد لمشتق بنزيميدازول وطريقة تحضيره - Google Patents

شكل بلوري جديد لمشتق بنزيميدازول وطريقة تحضيره

Info

Publication number
JO3592B1
JO3592B1 JOP/2016/0008A JOP20160008A JO3592B1 JO 3592 B1 JO3592 B1 JO 3592B1 JO P20160008 A JOP20160008 A JO P20160008A JO 3592 B1 JO3592 B1 JO 3592B1
Authority
JO
Jordan
Prior art keywords
crystalline form
novel crystalline
preparation
benzimidazole derivative
long
Prior art date
Application number
JOP/2016/0008A
Other languages
English (en)
Inventor
Hyun Ko Dong
Sun Kim Eun
Woo LEE Hyuk
Pyeong HEO Seung
Ju Kim Young
Hong Kweon Jae
Ah LEE Sung
Yun LEE Ji
Do Choi Kwang
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56417901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3592(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Application granted granted Critical
Publication of JO3592B1 publication Critical patent/JO3592B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بشكل بلوري جديد لمشتق بنزيميدازول وطريقة تحضيره. إن الشكل البلوري الجديد وفقاً للاختراع الحالي يتغير بصعوبة كيميائياً و/أو فيزيائياً في إطار شرط مُجهد بالضوء طويل الأمد، له استرطابية منخفضة، وله قدرة حث كهرباء ساكنة منخفضة للغاية، وبالتالي يكون مفيداً للصياغة، وبسبب الاستقرار الممتاز للشكل البلوري نفسه، فإنه مفيد جداً من أجل تخزين طويل الأمد للمركب.
JOP/2016/0008A 2015-01-20 2016-01-19 شكل بلوري جديد لمشتق بنزيميدازول وطريقة تحضيره JO3592B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150009326A KR101684053B1 (ko) 2015-01-20 2015-01-20 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법

Publications (1)

Publication Number Publication Date
JO3592B1 true JO3592B1 (ar) 2020-07-05

Family

ID=56417901

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0008A JO3592B1 (ar) 2015-01-20 2016-01-19 شكل بلوري جديد لمشتق بنزيميدازول وطريقة تحضيره

Country Status (32)

Country Link
US (1) US9908870B2 (ar)
EP (1) EP3248967B1 (ar)
JP (2) JP6535748B2 (ar)
KR (1) KR101684053B1 (ar)
CN (2) CN111187259B (ar)
AR (1) AR103444A1 (ar)
BR (1) BR102016001167B1 (ar)
CL (1) CL2017001377A1 (ar)
CO (1) CO2017005396A2 (ar)
CY (1) CY1123423T1 (ar)
DK (1) DK3248967T3 (ar)
EA (1) EA030919B1 (ar)
EC (1) ECSP17035416A (ar)
ES (1) ES2816646T3 (ar)
GE (1) GEP20196974B (ar)
HR (1) HRP20201275T1 (ar)
HU (1) HUE050979T2 (ar)
IL (1) IL253186B (ar)
JO (1) JO3592B1 (ar)
LT (1) LT3248967T (ar)
MX (1) MX359916B (ar)
MY (1) MY186830A (ar)
PH (2) PH12016000029A1 (ar)
PL (1) PL3248967T3 (ar)
PT (1) PT3248967T (ar)
RS (1) RS60758B1 (ar)
SA (1) SA517381904B1 (ar)
SG (1) SG10201509488YA (ar)
SI (1) SI3248967T1 (ar)
TW (1) TWI589575B (ar)
UY (1) UY36521A (ar)
WO (1) WO2016117814A2 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101829706B1 (ko) 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
KR20230114163A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법
KR20230114164A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 벤즈이미다졸 유도체의 공동 무정형 고형체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR20240028127A (ko) 2022-08-24 2024-03-05 위더스제약주식회사 테고프라잔 고체분산체 조성물
WO2024045255A1 (zh) * 2022-08-30 2024-03-07 上海皓元医药股份有限公司 一种特戈拉赞晶型b及其制备方法
KR20240109898A (ko) 2023-01-05 2024-07-12 위더스제약주식회사 무정형 테고프라잔 고체분산체
KR20240120271A (ko) 2023-01-31 2024-08-07 주식회사 엔비피헬스케어 신규한 테고프라잔 말론산 공무정형
WO2024171128A1 (en) * 2023-02-18 2024-08-22 Lee Pharma Limited Stable amorphous form of potassium-competitive acid blocker and process for the preparation thereof
KR20240131641A (ko) 2023-02-24 2024-09-02 엠에프씨 주식회사 신규 테고프라잔의 염 결정형 및 이의 용매화물 결정형, 및 이들의 제조방법
KR102715562B1 (ko) 2023-03-16 2024-10-11 (주) 에프엔지리서치 테고프라잔의 신규 염 및 이의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043063A1 (es) 2002-12-13 2005-07-13 Altana Pharma Ag Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
DE602006009105D1 (de) * 2005-06-14 2009-10-22 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
CA2631880C (en) * 2005-12-19 2011-03-29 Pfizer Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
EP2650299A1 (en) * 2008-07-03 2013-10-16 Ratiopharm GmbH Crystalline salts of sitagliptin
EP2452680B1 (en) * 2009-07-09 2019-12-18 RaQualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
JP2014047304A (ja) * 2012-08-31 2014-03-17 Sanyo Chem Ind Ltd 樹脂粒子の製造方法
GB2508352B (en) * 2012-11-28 2017-08-16 Douwe Egberts Bv Treating soluble coffee
US8987459B2 (en) * 2013-01-11 2015-03-24 Novartis Ag Compounds for the treatment of conditions associated with DGAT1 activity
NZ732002A (en) * 2014-12-19 2023-07-28 Univ Court Univ Of Edinburgh 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors

Also Published As

Publication number Publication date
US20180009791A1 (en) 2018-01-11
SG10201509488YA (en) 2016-08-30
KR20160089928A (ko) 2016-07-29
EA201791151A1 (ru) 2017-12-29
CN107207478B (zh) 2020-09-01
CN111187259B (zh) 2023-10-13
AR103444A1 (es) 2017-05-10
WO2016117814A3 (ko) 2016-10-06
KR101684053B1 (ko) 2016-12-08
TWI589575B (zh) 2017-07-01
IL253186A (en) 2018-04-30
WO2016117814A2 (ko) 2016-07-28
PL3248967T3 (pl) 2020-12-28
CO2017005396A2 (es) 2017-07-11
HRP20201275T1 (hr) 2020-11-13
MX359916B (es) 2018-10-15
JP2018502140A (ja) 2018-01-25
BR102016001167B1 (pt) 2023-03-07
EP3248967B1 (en) 2020-06-24
SA517381904B1 (ar) 2020-12-07
ECSP17035416A (es) 2017-11-30
CN111187259A (zh) 2020-05-22
PH12016000029B1 (en) 2017-07-24
MX2016000751A (es) 2016-08-11
CY1123423T1 (el) 2021-12-31
PT3248967T (pt) 2020-09-11
CN107207478A (zh) 2017-09-26
EA030919B1 (ru) 2018-10-31
JP6535748B2 (ja) 2019-06-26
UY36521A (es) 2016-08-31
IL253186B (en) 2020-11-30
ES2816646T3 (es) 2021-04-05
LT3248967T (lt) 2020-10-12
HUE050979T2 (hu) 2021-01-28
GEP20196974B (en) 2019-06-10
TW201627305A (zh) 2016-08-01
EP3248967A4 (en) 2018-10-03
JP2019104760A (ja) 2019-06-27
BR102016001167A2 (pt) 2018-03-20
CL2017001377A1 (es) 2017-12-15
RS60758B1 (sr) 2020-10-30
EP3248967A2 (en) 2017-11-29
SI3248967T1 (sl) 2020-11-30
DK3248967T3 (da) 2020-09-07
PH12016000029A1 (en) 2017-07-24
US9908870B2 (en) 2018-03-06
PH12019000462A1 (en) 2020-10-12
MY186830A (en) 2021-08-24

Similar Documents

Publication Publication Date Title
PH12019000462A1 (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12018500341A1 (en) Heterocyclic amides as kinase inhibitors
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
MX2022009299A (es) Derivado de quinolina muy puro y metodo para su produccion.
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX2018003280A (es) Proceso de compuesto antifungico.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
MX2015014688A (es) Tiazoles y usos de los mismos.
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
MX2015017156A (es) Inhibidores de bace.
BR112019025028A2 (pt) Método para preparar um composto.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
AU2016299728A8 (en) Substituierted Furano-/Thienocycloalkylamino-2-Pyrimidine derivatives and use thereof for controlling undesired plant growth
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors
IN2013DE02503A (ar)
TW201613944A (en) Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.